Annual Accounts Receivable
N/A
December 1, 2024
Summary
- PFE annual accounts receivable is not available.
Performance
PFE Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
N/A
December 1, 2024
Summary
- PFE quarterly accounts receivable is not available.
Performance
PFE Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PFE Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
PFE Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time |
Pfizer Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $14.45 B(+26.8%) |
| Jun 2024 | - | $11.39 B(+3.7%) |
| Mar 2024 | - | $10.99 B(-1.7%) |
| Dec 2023 | $11.18 B(+2.1%) | $11.18 B(+0.8%) |
| Sep 2023 | - | $11.09 B(+8.4%) |
| Jun 2023 | - | $10.23 B(-16.9%) |
| Mar 2023 | - | $12.30 B(+12.4%) |
| Dec 2022 | $10.95 B(-4.6%) | $10.95 B(-31.9%) |
| Sep 2022 | - | $16.08 B(+6.1%) |
| Jun 2022 | - | $15.15 B(+14.6%) |
| Mar 2022 | - | $13.22 B(+15.2%) |
| Dec 2021 | $11.48 B(+45.1%) | $11.48 B(-3.5%) |
| Sep 2021 | - | $11.90 B(+12.4%) |
| Jun 2021 | - | $10.59 B(+7.3%) |
| Mar 2021 | - | $9.86 B(+24.7%) |
| Dec 2020 | $7.91 B(+16.8%) | $7.91 B(-21.0%) |
| Sep 2020 | - | $10.01 B(+9.7%) |
| Jun 2020 | - | $9.13 B(-7.6%) |
| Mar 2020 | - | $9.88 B(+45.9%) |
| Dec 2019 | $6.77 B(-15.6%) | $6.77 B(-28.3%) |
| Sep 2019 | - | $9.44 B(-3.6%) |
| Jun 2019 | - | $9.79 B(+2.0%) |
| Mar 2019 | - | $9.60 B(+19.6%) |
| Dec 2018 | $8.03 B(-2.4%) | $8.03 B(-19.9%) |
| Sep 2018 | - | $10.02 B(+1.5%) |
| Jun 2018 | - | $9.87 B(+4.5%) |
| Mar 2018 | - | $9.45 B(+15.0%) |
| Dec 2017 | $8.22 B(-0.0%) | $8.22 B(-17.8%) |
| Sep 2017 | - | $10.00 B(+5.6%) |
| Jun 2017 | - | $9.48 B(+6.6%) |
| Mar 2017 | - | $8.89 B(+8.1%) |
| Dec 2016 | $8.22 B(+0.6%) | $8.22 B(-16.4%) |
| Sep 2016 | - | $9.84 B(+7.6%) |
| Jun 2016 | - | $9.14 B(+1.2%) |
| Mar 2016 | - | $9.03 B(+10.5%) |
| Dec 2015 | $8.18 B(-2.7%) | $8.18 B(-14.3%) |
| Sep 2015 | - | $9.54 B(+6.5%) |
| Jun 2015 | - | $8.95 B(+0.3%) |
| Mar 2015 | - | $8.92 B(+6.2%) |
| Dec 2014 | $8.40 B(-10.2%) | $8.40 B(-15.6%) |
| Sep 2014 | - | $9.96 B(-4.2%) |
| Jun 2014 | - | $10.39 B(+10.5%) |
| Mar 2014 | - | $9.40 B(+0.4%) |
| Dec 2013 | $9.36 B(-12.3%) | $9.36 B(-17.7%) |
| Sep 2013 | - | $11.37 B(-1.3%) |
| Jun 2013 | - | $11.52 B(-9.5%) |
| Mar 2013 | - | $12.73 B(+19.3%) |
| Dec 2012 | $10.68 B | $10.68 B(-14.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2012 | - | $12.52 B(-2.8%) |
| Jun 2012 | - | $12.88 B(-9.2%) |
| Mar 2012 | - | $14.18 B(+8.6%) |
| Dec 2011 | $13.06 B(-10.6%) | $13.06 B(-17.1%) |
| Sep 2011 | - | $15.75 B(+3.7%) |
| Jun 2011 | - | $15.19 B(+0.1%) |
| Mar 2011 | - | $15.18 B(+3.9%) |
| Dec 2010 | $14.61 B(-0.2%) | $14.61 B(+2.2%) |
| Sep 2010 | - | $14.30 B(+2.1%) |
| Jun 2010 | - | $14.01 B(+2.9%) |
| Mar 2010 | - | $13.61 B(-7.1%) |
| Dec 2009 | $14.64 B(+63.5%) | $14.64 B(+38.8%) |
| Sep 2009 | - | $10.55 B(+1.0%) |
| Jun 2009 | - | $10.45 B(+8.9%) |
| Mar 2009 | - | $9.60 B(+7.1%) |
| Dec 2008 | $8.96 B(-9.0%) | $8.96 B(-9.5%) |
| Sep 2008 | - | $9.90 B(-3.4%) |
| Jun 2008 | - | $10.24 B(-1.8%) |
| Mar 2008 | - | $10.43 B(+6.0%) |
| Dec 2007 | $9.84 B(+4.8%) | $9.84 B(-1.0%) |
| Sep 2007 | - | $9.94 B(+4.7%) |
| Jun 2007 | - | $9.50 B(-9.2%) |
| Mar 2007 | - | $10.46 B(+11.3%) |
| Dec 2006 | $9.39 B(+3.2%) | $9.39 B(+2.3%) |
| Sep 2006 | - | $9.18 B(-1.1%) |
| Jun 2006 | - | $9.28 B(-10.4%) |
| Mar 2006 | - | $10.35 B(+13.7%) |
| Dec 2005 | $9.10 B(-2.8%) | $9.10 B(-2.6%) |
| Sep 2005 | - | $9.35 B(+0.3%) |
| Jun 2005 | - | $9.32 B(-7.5%) |
| Mar 2005 | - | $10.07 B(+7.5%) |
| Dec 2004 | $9.37 B(+8.5%) | $9.37 B(+1.6%) |
| Sep 2004 | - | $9.22 B(-1.3%) |
| Jun 2004 | - | $9.34 B(-10.3%) |
| Mar 2004 | - | $10.41 B(+20.6%) |
| Dec 2003 | $8.64 B(+49.3%) | $8.64 B(+0.1%) |
| Sep 2003 | - | $8.63 B(-2.1%) |
| Jun 2003 | - | $8.81 B(+30.3%) |
| Mar 2003 | - | $6.76 B(+16.8%) |
| Dec 2002 | $5.79 B(+20.6%) | $5.79 B(-5.1%) |
| Sep 2002 | - | $6.10 B(-2.8%) |
| Jun 2002 | - | $6.27 B(-2.8%) |
| Mar 2002 | - | $6.45 B(+34.5%) |
| Dec 2001 | $4.80 B(-12.6%) | $4.80 B(-15.5%) |
| Sep 2001 | - | $5.68 B(+4.5%) |
| Jun 2001 | - | $5.43 B(-5.9%) |
| Mar 2001 | - | $5.77 B(+5.2%) |
| Dec 2000 | $5.49 B(+2.3%) | $5.49 B(+2.3%) |
| Dec 1999 | $5.37 B | $5.37 B |
FAQ
- What is the all time high annual accounts receivable for Pfizer?
- What is the all time high quarterly accounts receivable for Pfizer?
What is the all time high annual accounts receivable for Pfizer?
Pfizer all-time high annual accounts receivable is $14.64 B
What is the all time high quarterly accounts receivable for Pfizer?
Pfizer all-time high quarterly accounts receivable is $16.08 B